KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Assets Average (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Assets Average for 16 consecutive years, with $7.3 billion as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Assets Average rose 4.76% year-over-year to $7.3 billion, compared with a TTM value of $7.3 billion through Jun 2025, up 4.76%, and an annual FY2025 reading of $7.3 billion, up 5.44% over the prior year.
  • Assets Average was $7.3 billion for Q2 2025 at Biomarin Pharmaceutical, up from $7.1 billion in the prior quarter.
  • Across five years, Assets Average topped out at $7.3 billion in Q2 2025 and bottomed at $5.9 billion in Q3 2021.
  • Average Assets Average over 5 years is $6.5 billion, with a median of $6.4 billion recorded in 2023.
  • The sharpest move saw Assets Average dropped 0.2% in 2021, then increased 7.07% in 2024.
  • Year by year, Assets Average stood at $6.0 billion in 2021, then rose by 5.48% to $6.3 billion in 2022, then increased by 1.34% to $6.4 billion in 2023, then grew by 8.05% to $6.9 billion in 2024, then increased by 5.51% to $7.3 billion in 2025.
  • Business Quant data shows Assets Average for BMRN at $7.3 billion in Q2 2025, $7.1 billion in Q1 2025, and $6.9 billion in Q4 2024.